Related Experiment Videos
The potential effect of blood pressure reduction on cardiovascular disease. A cautionary note
Insights
Systolic blood pressure (BP) levels alone do not precisely predict cardiovascular disease (CVD) risk or the benefits of BP reduction. More comprehensive prognostic measures are needed for accurate CVD risk assessment.
Area of Science:
- Cardiology
- Epidemiology
- Preventive Medicine
Background:
- Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
- Accurate risk stratification is crucial for effective CVD prevention strategies.
- Systolic blood pressure (BP) is a primary modifiable risk factor for CVD.
Purpose of the Study:
- To estimate CVD risk at various systolic BP levels.
- To assess the potential benefits of systolic BP reduction.
- To identify limitations of systolic BP alone in predicting CVD outcomes.
Main Methods:
- Utilized Framingham Study data to construct probability tables for CVD.
- Analyzed CVD risk across different systolic BP ranges.
- Evaluated the variability in CVD risk and BP reduction benefits based on demographics and clinical characteristics.
Main Results:
- Systolic BP alone delineates subgroups with widely divergent CVD risk.
- Individuals with lower systolic BP can have higher CVD risk than those with higher BP.
- The prognostic value of initial systolic BP for predicting benefits of reduction is limited.
Conclusions:
- Systolic blood pressure is an important but insufficient predictor of CVD risk.
- Demographic and clinical factors significantly modify CVD risk at given BP levels.
- Enhanced prognostic measures beyond initial BP are necessary for precise CVD risk assessment and management.
Abstract:
The risk of cardiovascular disease (CVD) at various levels of systolic blood pressure (BP) and the potential benefit of BP reduction have been estimated by constructing probability tables for extended periods based on the Framingham Study data. These estimates demonstrate that systolic BP alone delineates subgroups of persons with widely divergent risk of CVD, depending both on their demographic and clinical characteristic. For example, the disparity in prognosis is such that some persons with a systolic BP of 160 mm Hg are at greater risk of subsequent CVD than others with a systolic BP of 195 mm Hg. The potential benefit to be derived from systolic BP reduction shows similarly wide variation, so initial pressure alone does not precisely predict the gain that might accompany BP reduction. Measures of greater prognostic value are needed to enhance the value of BP determination.